Skip to main content
SpringerLink
Log in

Preclinical pharmacokinetics of radiolabeled hyaluronan

  • Published:
Pharmacological Reports Aims and scope Submit manuscript

Abstract

Background

Hyaluronan (HYA) is a high molecular weight glucosaminoglycan with a great perspective for medical applications. Because HYA is widespread in the body, it is difficult to determine the fate of exogenously administered HYA.

Methods

In this study, HYAof different molecular weights (0.1–1 MDa) was labelled with 99mTc, and the distribution profiles were determined after administrating the HYA to rats.

Results

After the intravenous administration of 99mTc-HYA, a rapid decrease in the radioactivity of blood samples was observed, presumably because of 99mTc-HYA uptake by the liver; only minimal signs of liver radioactivity washout were detected. After the oral administration of 99mTc-HYA, no significant absorption to the central compartment was found. A preliminary study using 14C-HYA exhibited a different distribution profile than 99mTc-HYA because of the different administered dose and the fate of the degradation products. Even with 14C-HYA, only traces of radioactivity were absorbed after oral administration.

Conclusion

This paper provides quantitative information regarding the distribution parameters of radiolabelled HYA in preclinical experiments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Balogh L, Polyak A, Mathe D, Kiraly R, Thuroczy J, Terez M, Janoki G et al.: Absorption, uptake and tissue affinity of high-molecular-weight hyaluronan after oral administration in rats and dogs. J Agric Food Chem, 2008, 56, 10582–10593.

    Article  CAS  Google Scholar 

  2. Bucci LR, Turpin AA: Will the real hyaluronan please stand up? J Appl Nutr, 2004, 54, 10–33.

    CAS  Google Scholar 

  3. Cozikova D, Laznickova A, Hermannova M, Svanovsky E, Palek L, Buffa R, Sedova P et al.: Preparation and the kinetic stability of hyaluronan radiolabeled with 111In, 125I and 14C. J Pharm Biomed Anal, 2010, 52, 517–524.

    Article  CAS  Google Scholar 

  4. Evanko SP, Wight TN: Intracellular localization of hyaluronan in proliferating cells. J Histochem Cytochem, 1999, 43, 1331–1341.

    Article  Google Scholar 

  5. Fraser JRE, Laurent TC, Laurent UBG: Hyaluronan: its nature, distribution, function and turnover. J Intern Med 1997, 242, 27–33.

    Article  CAS  Google Scholar 

  6. Jiang D, Liang J, Noble PW: Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol, 2007, 23, 435–461.

    Article  CAS  Google Scholar 

  7. Kim J, Park K, Hahn SK: Effect of hyaluronic acid molecular weight on the morphology of quantum dot-hyaluronic acid conjugates. Int J Biol Macromol, 2008, 42, 41–45.

    Article  CAS  Google Scholar 

  8. Knudson W, Chow G, Knudson ChB: CD-44-mediated uptake and degradation of hyaluronan. Matrix Biol, 2002, 21, 15–23.

    Article  CAS  Google Scholar 

  9. Meléndez-Alafort L, Nadali A, Zangoni E, Banzato A, Rondina M, Rosato A, Mazzi U: Biokinetic and dosimetric studies of 188Re-hyaluronic acid: a new radiopharma-ceutical for treatment of hepatocellular carcinoma. Nucl Med Biol, 2009, 36, 693–701.

    Article  Google Scholar 

  10. Oh EJ, Park K, Kim KS, Kim J, Yang J-A, Kong J-H, Lee MY et al.: Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Control Release, 2010, 141, 2–12.

    Article  CAS  Google Scholar 

  11. Stern R, Asari AA, Sugahara KN: Hyaluronan fragments: An information-rich system. Eur J Cell Biol, 2006, 85, 699–715.

    Article  CAS  Google Scholar 

  12. Svanovsky E, Velebny V, Laznickova A, Laznicek M: The effect of molecular weight on the biodistribution pf hyaluronic acid radiolabeled with 111In after intravenous administration to rats. Eur J Drug Metab Pharmacokinet, 2008, 33, 149–157.

    Article  CAS  Google Scholar 

  13. Volpi N, Schiler J, Stern R, Soltes L: Role, metabolism, chemical modifications and applications of hyaluronan. Curr Med Chem, 2009, 16, 1718–1745.

    Article  CAS  Google Scholar 

  14. Westerberg G, Bergstrom M, Gustafson S, Lindqvist U, Sundin A, Langstrom B: Labelling of polysaccharides using [11C]cyanogen bromide. In vivo and in vitro evaluation of 11C-hyaluronan kinetics. Nucl Med Biol, 1995, 22, 251–256.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Heyrovskeho 1203, CZ-500 05, Hradec Kralove, Czech Republic

    Milan Laznicek, Alice Laznickova & Dagmar Cozikova

  2. Contipro C a.s., Dolni Dobrouc 401, CZ-561 02, Dolni Dobrouc, Czech Republic

    Dagmar Cozikova & Vladimir Velebny

Authors
  1. Milan Laznicek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alice Laznickova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dagmar Cozikova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vladimir Velebny
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Milan Laznicek.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Laznicek, M., Laznickova, A., Cozikova, D. et al. Preclinical pharmacokinetics of radiolabeled hyaluronan. Pharmacol. Rep 64, 428–437 (2012). https://doi.org/10.1016/S1734-1140(12)70784-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1016/S1734-1140(12)70784-3

Key words

Search

Navigation